nodes	percent_of_prediction	percent_of_DWPC	metapath
Methazolamide—CYP2D6—Hydroxyurea—head and neck cancer	0.156	0.458	CbGbCtD
Methazolamide—CA6—submandibular gland—head and neck cancer	0.0952	0.288	CbGeAlD
Methazolamide—CYP2C9—Fluorouracil—head and neck cancer	0.0651	0.191	CbGbCtD
Methazolamide—CYP2D6—Vinblastine—head and neck cancer	0.0552	0.162	CbGbCtD
Methazolamide—Hepatic insufficiency—Hydroxyurea—head and neck cancer	0.053	0.179	CcSEcCtD
Methazolamide—CYP3A4—Vinblastine—head and neck cancer	0.0351	0.103	CbGbCtD
Methazolamide—CA6—saliva—head and neck cancer	0.0343	0.104	CbGeAlD
Methazolamide—CA6—ear—head and neck cancer	0.0313	0.0947	CbGeAlD
Methazolamide—CYP3A4—Docetaxel—head and neck cancer	0.0289	0.085	CbGbCtD
Methazolamide—CA6—exocrine gland—head and neck cancer	0.0173	0.0524	CbGeAlD
Methazolamide—CA6—hair follicle—head and neck cancer	0.0165	0.0499	CbGeAlD
Methazolamide—CA6—mouth—head and neck cancer	0.013	0.0392	CbGeAlD
Methazolamide—Digestion impaired—Hydroxyurea—head and neck cancer	0.0123	0.0415	CcSEcCtD
Methazolamide—Bone marrow depression—Hydroxyurea—head and neck cancer	0.0121	0.0411	CcSEcCtD
Methazolamide—CA6—parotid gland—head and neck cancer	0.00903	0.0273	CbGeAlD
Methazolamide—CA6—saliva-secreting gland—head and neck cancer	0.00865	0.0261	CbGeAlD
Methazolamide—Tingling sensation—Fluorouracil—head and neck cancer	0.00734	0.0248	CcSEcCtD
Methazolamide—CA7—trachea—head and neck cancer	0.00688	0.0208	CbGeAlD
Methazolamide—Hepatic failure—Hydroxyurea—head and neck cancer	0.00662	0.0224	CcSEcCtD
Methazolamide—CA2—exocrine gland—head and neck cancer	0.00597	0.018	CbGeAlD
Methazolamide—CA2—hair follicle—head and neck cancer	0.00569	0.0172	CbGeAlD
Methazolamide—Pancytopenia—Vinblastine—head and neck cancer	0.00535	0.0181	CcSEcCtD
Methazolamide—CA12—connective tissue—head and neck cancer	0.00533	0.0161	CbGeAlD
Methazolamide—Pancytopenia—Hydroxyurea—head and neck cancer	0.00488	0.0165	CcSEcCtD
Methazolamide—Photosensitivity—Fluorouracil—head and neck cancer	0.00488	0.0165	CcSEcCtD
Methazolamide—Agranulocytosis—Vinblastine—head and neck cancer	0.00469	0.0159	CcSEcCtD
Methazolamide—CA6—head—head and neck cancer	0.00468	0.0141	CbGeAlD
Methazolamide—CA4—neck—head and neck cancer	0.0046	0.0139	CbGeAlD
Methazolamide—Drowsiness—Hydroxyurea—head and neck cancer	0.00458	0.0155	CcSEcCtD
Methazolamide—CA12—trachea—head and neck cancer	0.00447	0.0135	CbGeAlD
Methazolamide—CA2—mouth—head and neck cancer	0.00446	0.0135	CbGeAlD
Methazolamide—CA2—neck—head and neck cancer	0.00382	0.0115	CbGeAlD
Methazolamide—CA4—parotid gland—head and neck cancer	0.00375	0.0113	CbGeAlD
Methazolamide—Ill-defined disorder—Vinblastine—head and neck cancer	0.00364	0.0123	CcSEcCtD
Methazolamide—CA4—saliva-secreting gland—head and neck cancer	0.00359	0.0108	CbGeAlD
Methazolamide—Malaise—Vinblastine—head and neck cancer	0.00354	0.012	CcSEcCtD
Methazolamide—Vertigo—Vinblastine—head and neck cancer	0.00353	0.012	CcSEcCtD
Methazolamide—Leukopenia—Vinblastine—head and neck cancer	0.00352	0.0119	CcSEcCtD
Methazolamide—Pancytopenia—Fluorouracil—head and neck cancer	0.00351	0.0119	CcSEcCtD
Methazolamide—Hepatic failure—Docetaxel—head and neck cancer	0.00344	0.0116	CcSEcCtD
Methazolamide—Convulsion—Vinblastine—head and neck cancer	0.0034	0.0115	CcSEcCtD
Methazolamide—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.00338	0.0114	CcSEcCtD
Methazolamide—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.00332	0.0113	CcSEcCtD
Methazolamide—Discomfort—Vinblastine—head and neck cancer	0.0033	0.0112	CcSEcCtD
Methazolamide—Malaise—Hydroxyurea—head and neck cancer	0.00323	0.0109	CcSEcCtD
Methazolamide—Leukopenia—Hydroxyurea—head and neck cancer	0.00321	0.0109	CcSEcCtD
Methazolamide—CA5B—thyroid gland—head and neck cancer	0.00317	0.00959	CbGeAlD
Methazolamide—CA12—head—head and neck cancer	0.00314	0.00949	CbGeAlD
Methazolamide—CA2—parotid gland—head and neck cancer	0.00311	0.00939	CbGeAlD
Methazolamide—Convulsion—Hydroxyurea—head and neck cancer	0.0031	0.0105	CcSEcCtD
Methazolamide—CA1—lymphoid tissue—head and neck cancer	0.00309	0.00933	CbGeAlD
Methazolamide—Agranulocytosis—Fluorouracil—head and neck cancer	0.00308	0.0104	CcSEcCtD
Methazolamide—Anorexia—Vinblastine—head and neck cancer	0.00306	0.0103	CcSEcCtD
Methazolamide—Discomfort—Hydroxyurea—head and neck cancer	0.00301	0.0102	CcSEcCtD
Methazolamide—CA2—saliva-secreting gland—head and neck cancer	0.00298	0.009	CbGeAlD
Methazolamide—Paraesthesia—Vinblastine—head and neck cancer	0.00288	0.00975	CcSEcCtD
Methazolamide—CA5B—head—head and neck cancer	0.00282	0.00851	CbGeAlD
Methazolamide—Anorexia—Hydroxyurea—head and neck cancer	0.00279	0.00944	CcSEcCtD
Methazolamide—Decreased appetite—Vinblastine—head and neck cancer	0.00279	0.00944	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.00278	0.00942	CcSEcCtD
Methazolamide—CA4—trachea—head and neck cancer	0.00277	0.00837	CbGeAlD
Methazolamide—CA2—connective tissue—head and neck cancer	0.00274	0.00827	CbGeAlD
Methazolamide—Feeling abnormal—Vinblastine—head and neck cancer	0.00264	0.00895	CcSEcCtD
Methazolamide—Somnolence—Hydroxyurea—head and neck cancer	0.0026	0.0088	CcSEcCtD
Methazolamide—CA2—epithelium—head and neck cancer	0.0026	0.00785	CbGeAlD
Methazolamide—Dyspepsia—Hydroxyurea—head and neck cancer	0.00257	0.00871	CcSEcCtD
Methazolamide—Decreased appetite—Hydroxyurea—head and neck cancer	0.00254	0.00861	CcSEcCtD
Methazolamide—Pancytopenia—Docetaxel—head and neck cancer	0.00254	0.00859	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00252	0.00855	CcSEcCtD
Methazolamide—Fatigue—Hydroxyurea—head and neck cancer	0.00252	0.00854	CcSEcCtD
Methazolamide—CA1—head—head and neck cancer	0.00249	0.00751	CbGeAlD
Methazolamide—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00241	0.00816	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.00236	0.008	CcSEcCtD
Methazolamide—Body temperature increased—Hydroxyurea—head and neck cancer	0.00231	0.00783	CcSEcCtD
Methazolamide—Leukopenia—Fluorouracil—head and neck cancer	0.00231	0.00782	CcSEcCtD
Methazolamide—Asthenia—Vinblastine—head and neck cancer	0.0023	0.00779	CcSEcCtD
Methazolamide—CA2—trachea—head and neck cancer	0.0023	0.00694	CbGeAlD
Methazolamide—Convulsion—Fluorouracil—head and neck cancer	0.00223	0.00757	CcSEcCtD
Methazolamide—Agranulocytosis—Docetaxel—head and neck cancer	0.00222	0.00753	CcSEcCtD
Methazolamide—Diarrhoea—Vinblastine—head and neck cancer	0.00219	0.00743	CcSEcCtD
Methazolamide—CA4—thyroid gland—head and neck cancer	0.00219	0.00662	CbGeAlD
Methazolamide—Discomfort—Fluorouracil—head and neck cancer	0.00217	0.00734	CcSEcCtD
Methazolamide—Confusional state—Fluorouracil—head and neck cancer	0.00212	0.00719	CcSEcCtD
Methazolamide—Anaphylactic shock—Fluorouracil—head and neck cancer	0.0021	0.00713	CcSEcCtD
Methazolamide—Asthenia—Hydroxyurea—head and neck cancer	0.0021	0.0071	CcSEcCtD
Methazolamide—Vomiting—Vinblastine—head and neck cancer	0.00204	0.0069	CcSEcCtD
Methazolamide—Erythema multiforme—Docetaxel—head and neck cancer	0.00202	0.00685	CcSEcCtD
Methazolamide—Headache—Vinblastine—head and neck cancer	0.00201	0.0068	CcSEcCtD
Methazolamide—Anorexia—Fluorouracil—head and neck cancer	0.00201	0.00679	CcSEcCtD
Methazolamide—Diarrhoea—Hydroxyurea—head and neck cancer	0.002	0.00677	CcSEcCtD
Methazolamide—CA2—lymphoid tissue—head and neck cancer	0.002	0.00604	CbGeAlD
Methazolamide—CA5B—lymph node—head and neck cancer	0.00197	0.00596	CbGeAlD
Methazolamide—CA4—head—head and neck cancer	0.00194	0.00587	CbGeAlD
Methazolamide—Nausea—Vinblastine—head and neck cancer	0.0019	0.00645	CcSEcCtD
Methazolamide—Paraesthesia—Fluorouracil—head and neck cancer	0.00189	0.0064	CcSEcCtD
Methazolamide—Somnolence—Fluorouracil—head and neck cancer	0.00187	0.00634	CcSEcCtD
Methazolamide—Vomiting—Hydroxyurea—head and neck cancer	0.00186	0.00629	CcSEcCtD
Methazolamide—Dyspepsia—Fluorouracil—head and neck cancer	0.00185	0.00627	CcSEcCtD
Methazolamide—Rash—Hydroxyurea—head and neck cancer	0.00184	0.00624	CcSEcCtD
Methazolamide—Dermatitis—Hydroxyurea—head and neck cancer	0.00184	0.00624	CcSEcCtD
Methazolamide—Headache—Hydroxyurea—head and neck cancer	0.00183	0.0062	CcSEcCtD
Methazolamide—Decreased appetite—Fluorouracil—head and neck cancer	0.00183	0.00619	CcSEcCtD
Methazolamide—Dysgeusia—Docetaxel—head and neck cancer	0.00182	0.00617	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00182	0.00615	CcSEcCtD
Methazolamide—CA2—thyroid gland—head and neck cancer	0.00182	0.00549	CbGeAlD
Methazolamide—CA1—lymph node—head and neck cancer	0.00174	0.00526	CbGeAlD
Methazolamide—Nausea—Hydroxyurea—head and neck cancer	0.00174	0.00588	CcSEcCtD
Methazolamide—Feeling abnormal—Fluorouracil—head and neck cancer	0.00173	0.00587	CcSEcCtD
Methazolamide—Urticaria—Fluorouracil—head and neck cancer	0.00167	0.00566	CcSEcCtD
Methazolamide—Leukopenia—Docetaxel—head and neck cancer	0.00167	0.00564	CcSEcCtD
Methazolamide—Body temperature increased—Fluorouracil—head and neck cancer	0.00166	0.00563	CcSEcCtD
Methazolamide—Convulsion—Docetaxel—head and neck cancer	0.00161	0.00546	CcSEcCtD
Methazolamide—CA2—head—head and neck cancer	0.00161	0.00487	CbGeAlD
Methazolamide—CYP2E1—lymphoid tissue—head and neck cancer	0.0016	0.00485	CbGeAlD
Methazolamide—Confusional state—Docetaxel—head and neck cancer	0.00153	0.00519	CcSEcCtD
Methazolamide—Anaphylactic shock—Docetaxel—head and neck cancer	0.00152	0.00514	CcSEcCtD
Methazolamide—CYP2E1—thyroid gland—head and neck cancer	0.00146	0.0044	CbGeAlD
Methazolamide—Anorexia—Docetaxel—head and neck cancer	0.00145	0.0049	CcSEcCtD
Methazolamide—Diarrhoea—Fluorouracil—head and neck cancer	0.00144	0.00488	CcSEcCtD
Methazolamide—Paraesthesia—Docetaxel—head and neck cancer	0.00136	0.00462	CcSEcCtD
Methazolamide—CA4—lymph node—head and neck cancer	0.00136	0.00411	CbGeAlD
Methazolamide—Somnolence—Docetaxel—head and neck cancer	0.00135	0.00457	CcSEcCtD
Methazolamide—Vomiting—Fluorouracil—head and neck cancer	0.00134	0.00453	CcSEcCtD
Methazolamide—Dyspepsia—Docetaxel—head and neck cancer	0.00134	0.00453	CcSEcCtD
Methazolamide—Rash—Fluorouracil—head and neck cancer	0.00133	0.00449	CcSEcCtD
Methazolamide—Dermatitis—Fluorouracil—head and neck cancer	0.00133	0.00449	CcSEcCtD
Methazolamide—Decreased appetite—Docetaxel—head and neck cancer	0.00132	0.00447	CcSEcCtD
Methazolamide—Headache—Fluorouracil—head and neck cancer	0.00132	0.00446	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00131	0.00444	CcSEcCtD
Methazolamide—Fatigue—Docetaxel—head and neck cancer	0.00131	0.00443	CcSEcCtD
Methazolamide—CYP2E1—head—head and neck cancer	0.00129	0.0039	CbGeAlD
Methazolamide—Feeling abnormal—Docetaxel—head and neck cancer	0.00125	0.00424	CcSEcCtD
Methazolamide—Nausea—Fluorouracil—head and neck cancer	0.00125	0.00423	CcSEcCtD
Methazolamide—Body temperature increased—Docetaxel—head and neck cancer	0.0012	0.00407	CcSEcCtD
Methazolamide—CA2—lymph node—head and neck cancer	0.00113	0.00341	CbGeAlD
Methazolamide—Asthenia—Docetaxel—head and neck cancer	0.00109	0.00369	CcSEcCtD
Methazolamide—Diarrhoea—Docetaxel—head and neck cancer	0.00104	0.00352	CcSEcCtD
Methazolamide—CYP2D6—head—head and neck cancer	0.00102	0.00309	CbGeAlD
Methazolamide—Vomiting—Docetaxel—head and neck cancer	0.000966	0.00327	CcSEcCtD
Methazolamide—Rash—Docetaxel—head and neck cancer	0.000958	0.00324	CcSEcCtD
Methazolamide—Dermatitis—Docetaxel—head and neck cancer	0.000957	0.00324	CcSEcCtD
Methazolamide—Headache—Docetaxel—head and neck cancer	0.000951	0.00322	CcSEcCtD
Methazolamide—Nausea—Docetaxel—head and neck cancer	0.000902	0.00306	CcSEcCtD
Methazolamide—CA9—HIF-1-alpha transcription factor network—VEGFA—head and neck cancer	0.000225	0.00668	CbGpPWpGaD
Methazolamide—CA1—Metabolism—UROD—head and neck cancer	0.000223	0.00663	CbGpPWpGaD
Methazolamide—CYP3A4—Xenobiotics—CYP1A1—head and neck cancer	0.00021	0.00624	CbGpPWpGaD
Methazolamide—CYP3A4—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000202	0.006	CbGpPWpGaD
Methazolamide—CA9—Metabolism—UROD—head and neck cancer	0.000196	0.00583	CbGpPWpGaD
Methazolamide—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000188	0.00559	CbGpPWpGaD
Methazolamide—CYP2E1—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000185	0.00551	CbGpPWpGaD
Methazolamide—CYP2E1—Biological oxidations—NAT2—head and neck cancer	0.000173	0.00514	CbGpPWpGaD
Methazolamide—CYP2E1—Metapathway biotransformation—NAT2—head and neck cancer	0.00017	0.00507	CbGpPWpGaD
Methazolamide—CYP2C19—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000169	0.00504	CbGpPWpGaD
Methazolamide—CYP2C19—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000168	0.00499	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—SOD2—head and neck cancer	0.000167	0.00498	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—GPX1—head and neck cancer	0.00016	0.00475	CbGpPWpGaD
Methazolamide—CYP2C9—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000154	0.00459	CbGpPWpGaD
Methazolamide—CYP2C9—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000153	0.00455	CbGpPWpGaD
Methazolamide—CA1—C-MYB transcription factor network—HRAS—head and neck cancer	0.000152	0.00453	CbGpPWpGaD
Methazolamide—CYP2E1—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000152	0.00453	CbGpPWpGaD
Methazolamide—CA14—Metabolism—NAT2—head and neck cancer	0.00015	0.00446	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—NAT2—head and neck cancer	0.000146	0.00434	CbGpPWpGaD
Methazolamide—CA6—Metabolism—NAT2—head and neck cancer	0.000146	0.00434	CbGpPWpGaD
Methazolamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000145	0.00431	CbGpPWpGaD
Methazolamide—CA9—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	0.000143	0.00426	CbGpPWpGaD
Methazolamide—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000143	0.00425	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—NAT2—head and neck cancer	0.000136	0.00406	CbGpPWpGaD
Methazolamide—CA7—Metabolism—NAT2—head and neck cancer	0.000136	0.00406	CbGpPWpGaD
Methazolamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000133	0.00396	CbGpPWpGaD
Methazolamide—CYP2C19—Biological oxidations—NAT2—head and neck cancer	0.000133	0.00396	CbGpPWpGaD
Methazolamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000132	0.00393	CbGpPWpGaD
Methazolamide—SLC22A6—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000132	0.00392	CbGpPWpGaD
Methazolamide—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000131	0.00391	CbGpPWpGaD
Methazolamide—CYP2C19—Metapathway biotransformation—NAT2—head and neck cancer	0.000131	0.00391	CbGpPWpGaD
Methazolamide—CA14—Metabolism—DPYD—head and neck cancer	0.000131	0.00391	CbGpPWpGaD
Methazolamide—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.00013	0.00388	CbGpPWpGaD
Methazolamide—CA6—Metabolism—DPYD—head and neck cancer	0.000128	0.00381	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—DPYD—head and neck cancer	0.000128	0.00381	CbGpPWpGaD
Methazolamide—CA12—Metabolism—NAT2—head and neck cancer	0.000126	0.00376	CbGpPWpGaD
Methazolamide—CA14—Metabolism—YAP1—head and neck cancer	0.000125	0.00371	CbGpPWpGaD
Methazolamide—CYP2D6—Biological oxidations—NAT2—head and neck cancer	0.000123	0.00365	CbGpPWpGaD
Methazolamide—CA6—Metabolism—YAP1—head and neck cancer	0.000122	0.00361	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—YAP1—head and neck cancer	0.000122	0.00361	CbGpPWpGaD
Methazolamide—CYP2C9—Biological oxidations—NAT2—head and neck cancer	0.000121	0.00361	CbGpPWpGaD
Methazolamide—CYP2D6—Metapathway biotransformation—NAT2—head and neck cancer	0.000121	0.0036	CbGpPWpGaD
Methazolamide—CYP2C9—Metapathway biotransformation—NAT2—head and neck cancer	0.00012	0.00356	CbGpPWpGaD
Methazolamide—CA7—Metabolism—DPYD—head and neck cancer	0.00012	0.00356	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—DPYD—head and neck cancer	0.00012	0.00356	CbGpPWpGaD
Methazolamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000117	0.00349	CbGpPWpGaD
Methazolamide—CA7—Metabolism—YAP1—head and neck cancer	0.000113	0.00337	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—YAP1—head and neck cancer	0.000113	0.00337	CbGpPWpGaD
Methazolamide—CA12—Metabolism—DPYD—head and neck cancer	0.000111	0.00329	CbGpPWpGaD
Methazolamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000108	0.00321	CbGpPWpGaD
Methazolamide—CYP3A4—Tryptophan metabolism—CYP1A1—head and neck cancer	0.000108	0.00321	CbGpPWpGaD
Methazolamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000107	0.00319	CbGpPWpGaD
Methazolamide—CA12—Metabolism—YAP1—head and neck cancer	0.000105	0.00313	CbGpPWpGaD
Methazolamide—CYP2E1—Vitamin A and Carotenoid Metabolism—MAPK1—head and neck cancer	0.000103	0.00307	CbGpPWpGaD
Methazolamide—CA4—Metabolism—NAT2—head and neck cancer	0.000101	0.003	CbGpPWpGaD
Methazolamide—CYP2C19—Arachidonic acid metabolism—PTGS2—head and neck cancer	9.97e-05	0.00297	CbGpPWpGaD
Methazolamide—CA2—Metabolism—NAT2—head and neck cancer	9.66e-05	0.00287	CbGpPWpGaD
Methazolamide—CA1—Metabolism—NAT2—head and neck cancer	9.26e-05	0.00275	CbGpPWpGaD
Methazolamide—CYP2C9—Arachidonic acid metabolism—PTGS2—head and neck cancer	9.09e-05	0.0027	CbGpPWpGaD
Methazolamide—CA4—Metabolism—DPYD—head and neck cancer	8.83e-05	0.00263	CbGpPWpGaD
Methazolamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	8.71e-05	0.00259	CbGpPWpGaD
Methazolamide—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	8.6e-05	0.00256	CbGpPWpGaD
Methazolamide—CYP2E1—Biological oxidations—GSTM1—head and neck cancer	8.53e-05	0.00254	CbGpPWpGaD
Methazolamide—CA2—Metabolism—DPYD—head and neck cancer	8.47e-05	0.00252	CbGpPWpGaD
Methazolamide—CYP2E1—Metapathway biotransformation—GSTM1—head and neck cancer	8.41e-05	0.0025	CbGpPWpGaD
Methazolamide—CA4—Metabolism—YAP1—head and neck cancer	8.38e-05	0.00249	CbGpPWpGaD
Methazolamide—CA9—Metabolism—NAT2—head and neck cancer	8.14e-05	0.00242	CbGpPWpGaD
Methazolamide—CA1—Metabolism—DPYD—head and neck cancer	8.12e-05	0.00241	CbGpPWpGaD
Methazolamide—CYP2E1—Biological oxidations—CYP1A1—head and neck cancer	8.09e-05	0.00241	CbGpPWpGaD
Methazolamide—CA2—Metabolism—YAP1—head and neck cancer	8.04e-05	0.00239	CbGpPWpGaD
Methazolamide—CYP3A4—Biological oxidations—NAT2—head and neck cancer	8.01e-05	0.00238	CbGpPWpGaD
Methazolamide—CYP2E1—Metapathway biotransformation—CYP1A1—head and neck cancer	7.97e-05	0.00237	CbGpPWpGaD
Methazolamide—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	7.9e-05	0.00235	CbGpPWpGaD
Methazolamide—CA1—Metabolism—YAP1—head and neck cancer	7.7e-05	0.00229	CbGpPWpGaD
Methazolamide—CA14—Metabolism—TYMS—head and neck cancer	7.49e-05	0.00223	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—VEGFA—head and neck cancer	7.41e-05	0.0022	CbGpPWpGaD
Methazolamide—CA14—Metabolism—GSTM1—head and neck cancer	7.4e-05	0.0022	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—STAT3—head and neck cancer	7.34e-05	0.00218	CbGpPWpGaD
Methazolamide—CA6—Metabolism—TYMS—head and neck cancer	7.3e-05	0.00217	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—TYMS—head and neck cancer	7.3e-05	0.00217	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—GSTM1—head and neck cancer	7.21e-05	0.00215	CbGpPWpGaD
Methazolamide—CA6—Metabolism—GSTM1—head and neck cancer	7.21e-05	0.00215	CbGpPWpGaD
Methazolamide—CA9—Metabolism—DPYD—head and neck cancer	7.14e-05	0.00212	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—UROD—head and neck cancer	7.11e-05	0.00212	CbGpPWpGaD
Methazolamide—CA14—Metabolism—GPX1—head and neck cancer	7.09e-05	0.00211	CbGpPWpGaD
Methazolamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	7.06e-05	0.0021	CbGpPWpGaD
Methazolamide—CA14—Metabolism—CYP1A1—head and neck cancer	7.02e-05	0.00209	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—MAPK3—head and neck cancer	7.01e-05	0.00208	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—GPX1—head and neck cancer	6.91e-05	0.00205	CbGpPWpGaD
Methazolamide—CA6—Metabolism—GPX1—head and neck cancer	6.91e-05	0.00205	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—CYP1A1—head and neck cancer	6.84e-05	0.00203	CbGpPWpGaD
Methazolamide—CA6—Metabolism—CYP1A1—head and neck cancer	6.84e-05	0.00203	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—TYMS—head and neck cancer	6.81e-05	0.00203	CbGpPWpGaD
Methazolamide—CA7—Metabolism—TYMS—head and neck cancer	6.81e-05	0.00203	CbGpPWpGaD
Methazolamide—CA9—Metabolism—YAP1—head and neck cancer	6.77e-05	0.00201	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—GSTM1—head and neck cancer	6.73e-05	0.002	CbGpPWpGaD
Methazolamide—CA7—Metabolism—GSTM1—head and neck cancer	6.73e-05	0.002	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—MAPK1—head and neck cancer	6.67e-05	0.00198	CbGpPWpGaD
Methazolamide—CYP2C19—Biological oxidations—GSTM1—head and neck cancer	6.58e-05	0.00196	CbGpPWpGaD
Methazolamide—CYP2C19—Metapathway biotransformation—GSTM1—head and neck cancer	6.49e-05	0.00193	CbGpPWpGaD
Methazolamide—CA7—Metabolism—GPX1—head and neck cancer	6.45e-05	0.00192	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—GPX1—head and neck cancer	6.45e-05	0.00192	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—CYP1A1—head and neck cancer	6.38e-05	0.0019	CbGpPWpGaD
Methazolamide—CA7—Metabolism—CYP1A1—head and neck cancer	6.38e-05	0.0019	CbGpPWpGaD
Methazolamide—CA12—Metabolism—TYMS—head and neck cancer	6.31e-05	0.00188	CbGpPWpGaD
Methazolamide—CA12—Metabolism—GSTM1—head and neck cancer	6.24e-05	0.00186	CbGpPWpGaD
Methazolamide—CYP2C19—Biological oxidations—CYP1A1—head and neck cancer	6.24e-05	0.00186	CbGpPWpGaD
Methazolamide—CYP2C19—Metapathway biotransformation—CYP1A1—head and neck cancer	6.15e-05	0.00183	CbGpPWpGaD
Methazolamide—CYP2D6—Biological oxidations—GSTM1—head and neck cancer	6.05e-05	0.0018	CbGpPWpGaD
Methazolamide—CYP2C9—Biological oxidations—GSTM1—head and neck cancer	6e-05	0.00178	CbGpPWpGaD
Methazolamide—CA12—Metabolism—GPX1—head and neck cancer	5.97e-05	0.00178	CbGpPWpGaD
Methazolamide—CYP2D6—Metapathway biotransformation—GSTM1—head and neck cancer	5.97e-05	0.00178	CbGpPWpGaD
Methazolamide—CYP2C9—Metapathway biotransformation—GSTM1—head and neck cancer	5.92e-05	0.00176	CbGpPWpGaD
Methazolamide—CA12—Metabolism—CYP1A1—head and neck cancer	5.91e-05	0.00176	CbGpPWpGaD
Methazolamide—CYP2D6—Biological oxidations—CYP1A1—head and neck cancer	5.74e-05	0.00171	CbGpPWpGaD
Methazolamide—CYP2C9—Biological oxidations—CYP1A1—head and neck cancer	5.69e-05	0.00169	CbGpPWpGaD
Methazolamide—CYP2D6—Metapathway biotransformation—CYP1A1—head and neck cancer	5.66e-05	0.00168	CbGpPWpGaD
Methazolamide—CYP2C9—Metapathway biotransformation—CYP1A1—head and neck cancer	5.61e-05	0.00167	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—TP53—head and neck cancer	5.6e-05	0.00167	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—UROD—head and neck cancer	5.49e-05	0.00163	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—UROD—head and neck cancer	5.05e-05	0.0015	CbGpPWpGaD
Methazolamide—CA4—Metabolism—TYMS—head and neck cancer	5.03e-05	0.0015	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—UROD—head and neck cancer	5e-05	0.00149	CbGpPWpGaD
Methazolamide—CA4—Metabolism—GSTM1—head and neck cancer	4.97e-05	0.00148	CbGpPWpGaD
Methazolamide—CA2—Metabolism—TYMS—head and neck cancer	4.83e-05	0.00144	CbGpPWpGaD
Methazolamide—CA2—Metabolism—GSTM1—head and neck cancer	4.77e-05	0.00142	CbGpPWpGaD
Methazolamide—CA4—Metabolism—GPX1—head and neck cancer	4.76e-05	0.00142	CbGpPWpGaD
Methazolamide—CA4—Metabolism—CYP1A1—head and neck cancer	4.72e-05	0.0014	CbGpPWpGaD
Methazolamide—CA1—Metabolism—TYMS—head and neck cancer	4.63e-05	0.00138	CbGpPWpGaD
Methazolamide—CA1—Metabolism—GSTM1—head and neck cancer	4.57e-05	0.00136	CbGpPWpGaD
Methazolamide—CA2—Metabolism—GPX1—head and neck cancer	4.57e-05	0.00136	CbGpPWpGaD
Methazolamide—CA2—Metabolism—CYP1A1—head and neck cancer	4.52e-05	0.00134	CbGpPWpGaD
Methazolamide—CA1—Metabolism—GPX1—head and neck cancer	4.38e-05	0.0013	CbGpPWpGaD
Methazolamide—CA1—Metabolism—CYP1A1—head and neck cancer	4.33e-05	0.00129	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	4.26e-05	0.00127	CbGpPWpGaD
Methazolamide—CA14—Metabolism—PTGS2—head and neck cancer	4.17e-05	0.00124	CbGpPWpGaD
Methazolamide—CA9—Metabolism—TYMS—head and neck cancer	4.07e-05	0.00121	CbGpPWpGaD
Methazolamide—CA6—Metabolism—PTGS2—head and neck cancer	4.07e-05	0.00121	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—PTGS2—head and neck cancer	4.07e-05	0.00121	CbGpPWpGaD
Methazolamide—CA9—Metabolism—GSTM1—head and neck cancer	4.02e-05	0.0012	CbGpPWpGaD
Methazolamide—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	3.96e-05	0.00118	CbGpPWpGaD
Methazolamide—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	3.9e-05	0.00116	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	3.88e-05	0.00115	CbGpPWpGaD
Methazolamide—CA9—Metabolism—GPX1—head and neck cancer	3.85e-05	0.00115	CbGpPWpGaD
Methazolamide—CA9—Metabolism—CYP1A1—head and neck cancer	3.81e-05	0.00113	CbGpPWpGaD
Methazolamide—CA7—Metabolism—PTGS2—head and neck cancer	3.8e-05	0.00113	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—PTGS2—head and neck cancer	3.8e-05	0.00113	CbGpPWpGaD
Methazolamide—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	3.75e-05	0.00112	CbGpPWpGaD
Methazolamide—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	3.7e-05	0.0011	CbGpPWpGaD
Methazolamide—CA14—Metabolism—PTEN—head and neck cancer	3.64e-05	0.00108	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—PTEN—head and neck cancer	3.55e-05	0.00105	CbGpPWpGaD
Methazolamide—CA6—Metabolism—PTEN—head and neck cancer	3.55e-05	0.00105	CbGpPWpGaD
Methazolamide—CA12—Metabolism—PTGS2—head and neck cancer	3.52e-05	0.00105	CbGpPWpGaD
Methazolamide—CA7—Metabolism—PTEN—head and neck cancer	3.31e-05	0.000985	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—PTEN—head and neck cancer	3.31e-05	0.000985	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—UROD—head and neck cancer	3.3e-05	0.000982	CbGpPWpGaD
Methazolamide—CA12—Metabolism—PTEN—head and neck cancer	3.07e-05	0.000912	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—NAT2—head and neck cancer	2.95e-05	0.000879	CbGpPWpGaD
Methazolamide—CA4—Metabolism—PTGS2—head and neck cancer	2.8e-05	0.000834	CbGpPWpGaD
Methazolamide—CA2—Metabolism—PTGS2—head and neck cancer	2.69e-05	0.0008	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—DPYD—head and neck cancer	2.59e-05	0.00077	CbGpPWpGaD
Methazolamide—CA1—Metabolism—PTGS2—head and neck cancer	2.58e-05	0.000767	CbGpPWpGaD
Methazolamide—CA14—Metabolism—PIK3CA—head and neck cancer	2.57e-05	0.000764	CbGpPWpGaD
Methazolamide—CA6—Metabolism—PIK3CA—head and neck cancer	2.5e-05	0.000744	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—PIK3CA—head and neck cancer	2.5e-05	0.000744	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—YAP1—head and neck cancer	2.46e-05	0.000731	CbGpPWpGaD
Methazolamide—CA4—Metabolism—PTEN—head and neck cancer	2.45e-05	0.000728	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.42e-05	0.00072	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	2.4e-05	0.000713	CbGpPWpGaD
Methazolamide—CA2—Metabolism—PTEN—head and neck cancer	2.34e-05	0.000698	CbGpPWpGaD
Methazolamide—CA7—Metabolism—PIK3CA—head and neck cancer	2.34e-05	0.000695	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—PIK3CA—head and neck cancer	2.34e-05	0.000695	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—NAT2—head and neck cancer	2.28e-05	0.000678	CbGpPWpGaD
Methazolamide—CA9—Metabolism—PTGS2—head and neck cancer	2.27e-05	0.000674	CbGpPWpGaD
Methazolamide—CA1—Metabolism—PTEN—head and neck cancer	2.25e-05	0.000669	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.21e-05	0.000656	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	2.18e-05	0.00065	CbGpPWpGaD
Methazolamide—CA12—Metabolism—PIK3CA—head and neck cancer	2.16e-05	0.000644	CbGpPWpGaD
Methazolamide—CA14—Metabolism—AKT1—head and neck cancer	2.1e-05	0.000624	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—NAT2—head and neck cancer	2.1e-05	0.000623	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—NAT2—head and neck cancer	2.08e-05	0.000618	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—AKT1—head and neck cancer	2.04e-05	0.000608	CbGpPWpGaD
Methazolamide—CA6—Metabolism—AKT1—head and neck cancer	2.04e-05	0.000608	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—DPYD—head and neck cancer	2e-05	0.000594	CbGpPWpGaD
Methazolamide—CA9—Metabolism—PTEN—head and neck cancer	1.98e-05	0.000588	CbGpPWpGaD
Methazolamide—CA7—Metabolism—AKT1—head and neck cancer	1.91e-05	0.000568	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—AKT1—head and neck cancer	1.91e-05	0.000568	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—YAP1—head and neck cancer	1.9e-05	0.000564	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—DPYD—head and neck cancer	1.84e-05	0.000547	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—DPYD—head and neck cancer	1.82e-05	0.000542	CbGpPWpGaD
Methazolamide—CA12—Metabolism—AKT1—head and neck cancer	1.77e-05	0.000526	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—YAP1—head and neck cancer	1.74e-05	0.000519	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—YAP1—head and neck cancer	1.73e-05	0.000514	CbGpPWpGaD
Methazolamide—CA4—Metabolism—PIK3CA—head and neck cancer	1.73e-05	0.000513	CbGpPWpGaD
Methazolamide—CA2—Metabolism—PIK3CA—head and neck cancer	1.65e-05	0.000492	CbGpPWpGaD
Methazolamide—CA1—Metabolism—PIK3CA—head and neck cancer	1.59e-05	0.000472	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—TYMS—head and neck cancer	1.48e-05	0.000439	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—GSTM1—head and neck cancer	1.46e-05	0.000434	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.42e-05	0.000424	CbGpPWpGaD
Methazolamide—CA4—Metabolism—AKT1—head and neck cancer	1.41e-05	0.000419	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—GPX1—head and neck cancer	1.4e-05	0.000416	CbGpPWpGaD
Methazolamide—CA9—Metabolism—PIK3CA—head and neck cancer	1.39e-05	0.000415	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—CYP1A1—head and neck cancer	1.38e-05	0.000411	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—NAT2—head and neck cancer	1.37e-05	0.000408	CbGpPWpGaD
Methazolamide—CA2—Metabolism—AKT1—head and neck cancer	1.35e-05	0.000402	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.3e-05	0.000386	CbGpPWpGaD
Methazolamide—CA1—Metabolism—AKT1—head and neck cancer	1.3e-05	0.000385	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.24e-05	0.00037	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—DPYD—head and neck cancer	1.2e-05	0.000357	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—YAP1—head and neck cancer	1.14e-05	0.000339	CbGpPWpGaD
Methazolamide—CA9—Metabolism—AKT1—head and neck cancer	1.14e-05	0.000339	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—TYMS—head and neck cancer	1.14e-05	0.000339	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.13e-05	0.000337	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—GSTM1—head and neck cancer	1.13e-05	0.000335	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—GPX1—head and neck cancer	1.08e-05	0.000321	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CYP1A1—head and neck cancer	1.07e-05	0.000317	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—TYMS—head and neck cancer	1.05e-05	0.000311	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—TYMS—head and neck cancer	1.04e-05	0.000309	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—GSTM1—head and neck cancer	1.04e-05	0.000308	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—GSTM1—head and neck cancer	1.03e-05	0.000305	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—GPX1—head and neck cancer	9.91e-06	0.000295	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—GPX1—head and neck cancer	9.83e-06	0.000292	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CYP1A1—head and neck cancer	9.81e-06	0.000292	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CYP1A1—head and neck cancer	9.73e-06	0.000289	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	8.76e-06	0.000261	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PTGS2—head and neck cancer	8.22e-06	0.000245	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	7.99e-06	0.000238	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PTEN—head and neck cancer	7.17e-06	0.000213	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—TYMS—head and neck cancer	6.85e-06	0.000204	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—GSTM1—head and neck cancer	6.77e-06	0.000201	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—GPX1—head and neck cancer	6.48e-06	0.000193	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CYP1A1—head and neck cancer	6.42e-06	0.000191	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PTGS2—head and neck cancer	6.34e-06	0.000189	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PTGS2—head and neck cancer	5.84e-06	0.000174	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PTGS2—head and neck cancer	5.78e-06	0.000172	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PTEN—head and neck cancer	5.53e-06	0.000165	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PTEN—head and neck cancer	5.09e-06	0.000151	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PIK3CA—head and neck cancer	5.06e-06	0.00015	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PTEN—head and neck cancer	5.05e-06	0.00015	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—AKT1—head and neck cancer	4.13e-06	0.000123	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PIK3CA—head and neck cancer	3.9e-06	0.000116	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PTGS2—head and neck cancer	3.82e-06	0.000113	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PIK3CA—head and neck cancer	3.59e-06	0.000107	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PIK3CA—head and neck cancer	3.56e-06	0.000106	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PTEN—head and neck cancer	3.33e-06	9.9e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—AKT1—head and neck cancer	3.19e-06	9.49e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—AKT1—head and neck cancer	2.93e-06	8.72e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—AKT1—head and neck cancer	2.91e-06	8.65e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PIK3CA—head and neck cancer	2.35e-06	6.98e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—AKT1—head and neck cancer	1.92e-06	5.7e-05	CbGpPWpGaD
